Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN

• Autores: Ana Custodio, Antonio Calles, Pedro Pérez Segura
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 12, Nº. 4, 2010, págs. 310-314
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.